Quality of Life After Contralateral Prophylactic Mastectomy in Newly Diagnosed High-Risk Breast Cancer Patients Who Underwent BRCA1/2 Gene Testing
- 20 January 2007
- journal article
- breast cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (3) , 285-291
- https://doi.org/10.1200/jco.2006.07.3890
Abstract
Purpose Recent studies indicate that high-risk breast cancer patients (ie, women who carry mutations in BRCA1/2 genes) who opt for contralateral prophylactic mastectomy (CPM) have a substantially reduced risk of developing contralateral breast cancer. However, the immediate and long-term impact of this decision on women's quality of life and psychosocial functioning is largely unknown. In this study, we compared the impact of BRCA1/2 genetic test result and CPM on these outcomes among newly diagnosed breast cancer patients who opted for CPM at the time of their definitive surgical treatment versus patients who did not. Patients and Methods Participants were 149 high-risk women who underwent genetic counseling and testing for alterations in the BRCA1/2 genes. We measured self-reported quality of life, cancer-specific distress, and genetic testing–specific distress using standardized instruments before receipt of genetic test results and again 1 and 12 months later. Results Compared with patients who chose ...Keywords
This publication has 36 references indexed in Scilit:
- Surgical decisions made by 158 women with hereditary breast cancer aged <50 yearsEuropean Journal of Surgical Oncology, 2005
- Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriersBritish Journal of Cancer, 2005
- Efficacy of Prophylactic Mastectomy in Women With Unilateral Breast Cancer: A Cancer Research Network ProjectJournal of Clinical Oncology, 2005
- Utilization of BRCA1/BRCA2 Mutation Testing in Newly Diagnosed Breast Cancer PatientsCancer Epidemiology, Biomarkers & Prevention, 2005
- Appropriateness of breast‐conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2Cancer, 2004
- Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation CarriersJournal of Clinical Oncology, 2004
- Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer DiagnosisArchives of Surgery, 2003
- Efficacy of Contralateral Prophylactic Mastectomy in Women With a Personal and Family History of Breast CancerJournal of Clinical Oncology, 2001
- Cancer Risks in BRCA2 Mutation CarriersJNCI Journal of the National Cancer Institute, 1999
- Unusual case of Smith‐Lemli‐Opitz syndrome “type II”American Journal of Medical Genetics, 1995